{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:25:25Z","timestamp":1789979125281,"version":"4.0.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T00:00:00Z","timestamp":1459987200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1038\/nrcardio.2016.48","type":"journal-article","created":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T08:25:03Z","timestamp":1460017503000},"page":"603-608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Global cardiovascular protection in chronic kidney disease"],"prefix":"10.1038","volume":"13","author":[{"given":"Gema","family":"Ruiz-Hurtado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Sarafidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda S.","family":"Fern\u00e1ndez-Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Waeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,7]]},"reference":[{"key":"BFnrcardio201648_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort, R. T.  et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382, 339\u2013352 (2013).","journal-title":"Lancet"},{"key":"BFnrcardio201648_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2010.483","volume":"80","author":"AS Levey","year":"2011","unstructured":"Levey, A. S.  et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 80, 17\u201328 (2011).","journal-title":"Kidney Int."},{"key":"BFnrcardio201648_CR3","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/nrcardio.2014.97","volume":"11","author":"G Ruiz-Hurtado","year":"2014","unstructured":"Ruiz-Hurtado, G. & Ruilope, L. M. Does cardiovascular protection translate into renal protection? Nat. Rev. Cardiol. 11, 742\u2013746 (2014).","journal-title":"Nat. Rev. Cardiol."},{"key":"BFnrcardio201648_CR4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James, P. A.  et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311, 507\u2013520 (2014).","journal-title":"JAMA"},{"key":"BFnrcardio201648_CR5","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia, G.  et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 34, 2159\u20132219 (2013).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201648_CR6","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"SR Group","year":"2015","unstructured":"Group, S. R. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103\u20132116 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201648_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrneph.2013.180","volume":"9","author":"LM Ruilope","year":"2013","unstructured":"Ruilope, L. M. Chronic kidney disease: blood pressure control in CKD \u2014 still a matter of debate. Nat. Rev. Nephrol. 9, 572\u2013573 (2013).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrcardio201648_CR8","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams, B.  et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386, 2059\u20132068 (2015).","journal-title":"Lancet"},{"key":"BFnrcardio201648_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1161\/HYPERTENSIONAHA.110.167189","volume":"57","author":"MP Schlaich","year":"2011","unstructured":"Schlaich, M. P. Sympathetic activation in chronic kidney disease: out of the shadow. Hypertension 57, 683\u2013685 (2011).","journal-title":"Hypertension"},{"key":"BFnrcardio201648_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/hr.2012.157","volume":"36","author":"AG Ptinopoulou","year":"2013","unstructured":"Ptinopoulou, A. G., Pikilidou, M. I. & Lasaridis, A. N. The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review. Hypertens. Res. 36, 91\u2013101 (2013).","journal-title":"Hypertens. Res."},{"key":"BFnrcardio201648_CR11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1046\/j.1445-5994.2002.00286.x","volume":"32","author":"DJ Campbell","year":"2002","unstructured":"Campbell, D. J. Renin\u2013angiotensin system inhibition: how much is too much of a good thing? Intern. Med. J. 32, 616\u2013620 (2002).","journal-title":"Intern. Med. J."},{"key":"BFnrcardio201648_CR12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","volume":"380","author":"M Tonelli","year":"2012","unstructured":"Tonelli, M.  et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380, 807\u2013814 (2012).","journal-title":"Lancet"},{"key":"BFnrcardio201648_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1161\/CIRCHEARTFAILURE.109.932558","volume":"4","author":"RK Wali","year":"2011","unstructured":"Wali, R. K.  et al. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. Circ. Heart Fail. 4, 18\u201326 (2011).","journal-title":"Circ. Heart Fail."},{"key":"BFnrcardio201648_CR14","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/MNH.0b013e32833ce6d5","volume":"19","author":"RD Toto","year":"2010","unstructured":"Toto, R. D. Aldosterone blockade in chronic kidney disease: can it improve outcome? Curr. Opin. Nephrol. Hypertens. 19, 444\u2013449 (2010).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"BFnrcardio201648_CR15","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"UF Mehdi","year":"2009","unstructured":"Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L. & Toto, R. D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2641\u20132650 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrcardio201648_CR16","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. Suppl. \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrcardio201648_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.mnh.0000444913.78536.b1","volume":"23","author":"MK Elliott","year":"2014","unstructured":"Elliott, M. K., McCaughan, J. A. & Fogarty, D. G. Do patients with chronic kidney disease get optimal cardiovascular risk reduction? Curr. Opin. Nephrol. Hypertens. 23, 267\u2013274 (2014).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"BFnrcardio201648_CR18","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.semnephrol.2014.10.002","volume":"34","author":"DJ Goldsmith","year":"2014","unstructured":"Goldsmith, D. J., Massy, Z. A. & Brandenburg, V. The uses and abuses of vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD). Semin. Nephrol. 34, 660\u2013668 (2014).","journal-title":"Semin. Nephrol."},{"key":"BFnrcardio201648_CR19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1161\/HYPERTENSIONAHA.114.03748","volume":"64","author":"C Zoccali","year":"2014","unstructured":"Zoccali, C.  et al. Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension 64, 1005\u20131011 (2014).","journal-title":"Hypertension"},{"key":"BFnrcardio201648_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1681\/ASN.2015050502","volume":"27","author":"RJ Johnson","year":"2016","unstructured":"Johnson, R. J. & Nangaku, M. Endothelial dysfunction: the secret agent driving kidney disease. J. Am. Soc. Nephrol. 27, 3\u20135 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrcardio201648_CR21","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","volume":"298","author":"J Coresh","year":"2007","unstructured":"Coresh, J.  et al. Prevalence of chronic kidney disease in the United States. JAMA 298, 2038\u20132047 (2007).","journal-title":"JAMA"},{"key":"BFnrcardio201648_CR22","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2012.16817","volume":"308","author":"SI Hallan","year":"2012","unstructured":"Hallan, S. I.  et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 308, 2349\u20132360 (2012).","journal-title":"JAMA"},{"key":"BFnrcardio201648_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","volume":"379","author":"AS Levey","year":"2012","unstructured":"Levey, A. S. & Coresh, J. Chronic kidney disease. Lancet 379, 165\u2013180 (2012).","journal-title":"Lancet"},{"key":"BFnrcardio201648_CR24","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/archinte.168.20.2268","volume":"168","author":"LC Plantinga","year":"2008","unstructured":"Plantinga, L. C.  et al. Patient awareness of chronic kidney disease: trends and predictors. Arch. Intern. Med. 168, 2268\u20132275 (2008).","journal-title":"Arch. Intern. Med."},{"key":"BFnrcardio201648_CR25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1159\/000350377","volume":"37","author":"JM Sontrop","year":"2013","unstructured":"Sontrop, J. M.  et al. Association between water intake, chronic kidney disease, and cardiovascular disease: a cross-sectional analysis of NHANES data. Am. J. Nephrol. 37, 434\u2013442 (2013).","journal-title":"Am. J. Nephrol."},{"key":"BFnrcardio201648_CR26","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/eurheartj\/ehr003","volume":"32","author":"LM Ruilope","year":"2011","unstructured":"Ruilope, L. M., Bakris, G. L. Renal function & target organ damage in hypertension. Eur. Heart J. 32, 1599\u20131604 (2011).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201648_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","volume":"34","author":"I Lazich","year":"2014","unstructured":"Lazich, I. & Bakris, G. L. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin. Nephrol. 34, 333\u2013339 (2014).","journal-title":"Semin. Nephrol."},{"key":"BFnrcardio201648_CR28","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/MAJ.0000000000000475","volume":"349","author":"S Shirazian","year":"2015","unstructured":"Shirazian, S.  et al. Underprescription of renin\u2013angiotensin system blockers in moderate to severe chronic kidney disease. Am. J. Med. Sci. 349, 510\u2013515 (2015).","journal-title":"Am. J. Med. Sci."},{"key":"BFnrcardio201648_CR29","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","volume":"169","author":"LM Einhorn","year":"2009","unstructured":"Einhorn, L. M.  et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch. Intern. Med. 169, 1156\u20131162 (2009).","journal-title":"Arch. Intern. Med."},{"key":"BFnrcardio201648_CR30","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","volume":"109","author":"N Jain","year":"2012","unstructured":"Jain, N.  et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am. J. Cardiol. 109, 1510\u20131513 (2012).","journal-title":"Am. J. Cardiol."},{"key":"BFnrcardio201648_CR31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1681\/ASN.2008020159","volume":"20","author":"O Moranne","year":"2009","unstructured":"Moranne, O.  et al. Timing of onset of CKD-related metabolic complications. J. Am. Soc. Nephrol. 20, 164\u2013171 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrcardio201648_CR32","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried, L. F.  et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 369, 1892\u20131903 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201648_CR33","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for acute kidney injury. Kidney Int. Suppl. \n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrcardio201648_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000440986","volume":"42","author":"A Saratzis","year":"2015","unstructured":"Saratzis, A.  et al. Intervention associated acute kidney injury and long-term cardiovascular outcomes. Am. J. Nephrol. 42, 285\u2013294 (2015).","journal-title":"Am. J. Nephrol."},{"key":"BFnrcardio201648_CR35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev-med-050214-013407","volume":"67","author":"A Zuk","year":"2016","unstructured":"Zuk, A. & Bonventre, J. V. Acute kidney injury. Annu. Rev. Med. 67, 293\u2013307 (2016).","journal-title":"Annu. Rev. Med."},{"key":"BFnrcardio201648_CR36","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","volume":"385","author":"SC Palmer","year":"2015","unstructured":"Palmer, S. C.  et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 385, 2047\u20132056 (2015).","journal-title":"Lancet"},{"key":"BFnrcardio201648_CR37","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato, A., Hayashi, K., Naruse, M. & Saruta, T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41, 64\u201368 (2003).","journal-title":"Hypertension"},{"key":"BFnrcardio201648_CR38","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1161\/CIRCRESAHA.116.302706","volume":"116","author":"CM Ferrario","year":"2015","unstructured":"Ferrario, C. M. & Schiffrin, E. L. Role of mineralocorticoid receptor antagonists in cardiovascular disease. Circ. Res. 116, 206\u2013213 (2015).","journal-title":"Circ. Res."},{"key":"BFnrcardio201648_CR39","first-page":"1110","volume":"304","author":"J Staessen","year":"1981","unstructured":"Staessen, J., Lijnen, P., Fagard, R., Verschueren, L. J. & Amery, A. Rise of plasma aldosterone during long-term captopril treatment. N. Engl. J. Med. 304, 1110 (1981).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201648_CR40","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1097\/01.ASN.0000086472.65806.73","volume":"14","author":"TH Hostetter","year":"2003","unstructured":"Hostetter, T. H. & Ibrahim, H. N. Aldosterone in chronic kidney and cardiac disease. J. Am. Soc. Nephrol. 14, 2395\u20132401 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrcardio201648_CR41","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.2215\/CJN.06960712","volume":"8","author":"O Moranne","year":"2013","unstructured":"Moranne, O.  et al. Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin. J. Am. Soc. Nephrol. 8, 1694\u20131701 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrcardio201648_CR42","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s11906-006-0060-5","volume":"8","author":"GP Rossi","year":"2006","unstructured":"Rossi, G. P. Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists? Curr. Hypertens. Rep. 8, 262\u2013268 (2006).","journal-title":"Curr. Hypertens. Rep."},{"key":"BFnrcardio201648_CR43","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/eurheartj\/ehu078","volume":"35","author":"E Sorbets","year":"2014","unstructured":"Sorbets, E.  et al. Renin\u2013angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. Eur. Heart J. 35, 1760\u20131768 (2014).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201648_CR44","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1093\/eurheartj\/ehu129","volume":"35","author":"LM Ruilope","year":"2014","unstructured":"Ruilope, L. M. Renin\u2013angiotensin system blockade: time for a reappraisal? Eur. Heart J. 35, 1703\u20131705 (2014).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201648_CR45","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ijcard.2014.11.004","volume":"177","author":"P Rossignol","year":"2014","unstructured":"Rossignol, P., Zannad, F. & Pitt, B. Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries. Int. J. Cardiol. 177, 731\u2013733 (2014).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio201648_CR46","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving, H. H.  et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204\u20132213 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201648_CR47","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1517\/14656566.2015.1079623","volume":"16","author":"DF M\u00e1rquez","year":"2015","unstructured":"M\u00e1rquez, D. F., Ruiz-Hurtado, G., Ruilope, L. M. & Segura, J. An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Expert Opin. Pharmacother. 16, 2283\u20132292 (2015).","journal-title":"Expert Opin. Pharmacother."},{"key":"BFnrcardio201648_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijcard.2013.12.125","volume":"172","author":"RE Schmieder","year":"2014","unstructured":"Schmieder, R. E., Volpe, M., Waeber, B. & Ruilope, L. M. A guide for easy- and difficult-to-treat hypertension. Int. J. Cardiol. 172, 17\u201322 (2014).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio201648_CR49","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000237742","volume":"30","author":"N Khosla","year":"2009","unstructured":"Khosla, N., Kalaitzidis, R. & Bakris, G. L. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am. J. Nephrol. 30, 418\u2013424 (2009).","journal-title":"Am. J. Nephrol."},{"key":"BFnrcardio201648_CR50","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1093\/eurheartj\/ehv192","volume":"36","author":"F Mahfoud","year":"2015","unstructured":"Mahfoud, F.  et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur. Heart J. 36, 2219\u20132227 (2015).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201648_CR51","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/eurjhf\/hfq212","volume":"13","author":"H Krum","year":"2011","unstructured":"Krum, H.  et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur. J. Heart Fail. 13, 107\u2013114 (2011).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio201648_CR52","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2012020164","volume":"23","author":"TC Turin","year":"2012","unstructured":"Turin, T. C.  et al. Lifetime risk of ESRD. J. Am. Soc. Nephrol. 23, 1569\u20131578 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrcardio201648_CR53","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L B\u00e4rfacker","year":"2012","unstructured":"B\u00e4rfacker, L.  et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7, 1385\u20131403 (2012).","journal-title":"ChemMedChem"},{"key":"BFnrcardio201648_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof, P.  et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J. Cardiovasc. Pharmacol. 64, 69\u201378 (2014).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"BFnrcardio201648_CR55","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt, B.  et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 34, 2453\u20132463 (2013).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201648_CR56","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris, G. L.  et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314, 884\u2013894 (2015).","journal-title":"JAMA"},{"key":"BFnrcardio201648_CR57","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMra035279","volume":"351","author":"BF Palmer","year":"2004","unstructured":"Palmer, B. F. Managing hyperkalemia caused by inhibitors of the renin\u2013angiotensin\u2013aldosterone system. N. Engl. J. Med. 351, 585\u2013592 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201648_CR58","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/SMJ.0b013e31819e8978","volume":"102","author":"CE McGowan","year":"2009","unstructured":"McGowan, C. E., Saha, S., Chu, G., Resnick, M. B. & Moss, S. F. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med. J. 102, 493\u2013497 (2009).","journal-title":"South Med. J."},{"key":"BFnrcardio201648_CR59","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1681\/ASN.2010010079","volume":"21","author":"RH Sterns","year":"2010","unstructured":"Sterns, R. H., Rojas, M., Bernstein, P. & Chennupati, S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J. Am. Soc. Nephrol. 21, 733\u2013735 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrcardio201648_CR60","doi-asserted-by":"publisher","first-page":"264.e9","DOI":"10.1016\/j.amjmed.2012.08.016","volume":"126","author":"Z Harel","year":"2013","unstructured":"Harel, Z.  et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am. J. Med. 126, 264.e9\u2013264.e24 (2013).","journal-title":"Am. J. Med."},{"key":"BFnrcardio201648_CR61","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir, M. R.  et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N. Engl. J. Med. 372, 211\u2013221 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201648_CR62","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod, M.  et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 312, 2223\u20132233 (2014).","journal-title":"JAMA"},{"key":"BFnrcardio201648_CR63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2217\/fca.11.71","volume":"8","author":"JM Buysse","year":"2012","unstructured":"Buysse, J. M., Huang, I. Z. & Pitt, B. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol. 8, 17\u201328 (2012).","journal-title":"Future Cardiol."},{"key":"BFnrcardio201648_CR64","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2015.7446","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris, G. L.  et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 314, 151\u2013161 (2015).","journal-title":"JAMA"},{"key":"BFnrcardio201648_CR65","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","volume":"17","author":"JB Kostis","year":"2004","unstructured":"Kostis, J. B.  et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment versus Enalapril (OCTAVE) trial. Am. J. Hypertens. 17, 103\u2013111 (2004).","journal-title":"Am. J. Hypertens."},{"key":"BFnrcardio201648_CR66","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1517\/13543784.2013.797962","volume":"22","author":"J Segura","year":"2013","unstructured":"Segura, J., Salazar, J. & Ruilope, L. M. Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. Expert Opin. Investig. Drugs 22, 915\u2013925 (2013).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BFnrcardio201648_CR67","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"Ruilope, L. M.  et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375, 1255\u20131266 (2010).","journal-title":"Lancet"},{"key":"BFnrcardio201648_CR68","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray, J. J.  et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993\u20131004 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201648_CR69","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ijcard.2014.11.059","volume":"179","author":"F Bodey","year":"2015","unstructured":"Bodey, F., Hopper, I. & Krum, H. Neprilysin inhibitors preserve renal function in heart failure. Int. J. Cardiol. 179, 329\u2013330 (2015).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio201648_CR70","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","volume":"157","author":"SC Palmer","year":"2012","unstructured":"Palmer, S. C.  et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann. Intern. Med. 157, 263\u2013275 (2012).","journal-title":"Ann. Intern. Med."},{"key":"BFnrcardio201648_CR71","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstr\u00f6m","year":"2009","unstructured":"Fellstr\u00f6m, B. C.  et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395\u20131407 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201648_CR72","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner, C.  et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238\u2013248 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201648_CR73","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1681\/ASN.2010090987","volume":"22","author":"H Holdaas","year":"2011","unstructured":"Holdaas, H.  et al. Rosuvastatin in diabetic hemodialysis patients. J. Am. Soc. Nephrol. 22, 1335\u20131341 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrcardio201648_CR74","unstructured":"Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am. Heart J. 160, 785\u2013794.e10 (2010)."},{"key":"BFnrcardio201648_CR75","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon, C. P.  et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387\u20132397 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201648_CR76","first-page":"F433","volume":"15","author":"P Wahl","year":"2015","unstructured":"Wahl, P., Ducasa, G. M. & Fornoni, A. Systemic and renal lipids in kidney disease development and progression. Am. J. Physiol. Renal Physiol. 15, F433\u2013F445 (2015).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrcardio201648_CR77","first-page":"CD007784","volume":"5","author":"SC Palmer","year":"2014","unstructured":"Palmer, S. C.  et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 5, CD007784 (2014).","journal-title":"Cochrane Database Syst Rev."},{"key":"BFnrcardio201648_CR78","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1517\/14656566.2015.1053464","volume":"16","author":"VG Athyros","year":"2015","unstructured":"Athyros, V. G., Katsiki, N., Karagiannis, A. & Mikhailidis, D. P. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? Expert Opin. Pharmacother. 16, 1449\u20131461 (2015).","journal-title":"Expert Opin. Pharmacother."},{"key":"BFnrcardio201648_CR79","doi-asserted-by":"publisher","first-page":"e0132970","DOI":"10.1371\/journal.pone.0132970","volume":"10","author":"A Sanguankeo","year":"2015","unstructured":"Sanguankeo, A., Upala, S., Cheungpasitporn, W., Ungprasert, P. & Knight, E. L. Effects of statins on renal outcome in chronic kidney disease patients: a systematic review and meta-analysis. PLoS ONE 10, e0132970 (2015).","journal-title":"PLoS ONE"},{"key":"BFnrcardio201648_CR80","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1681\/ASN.2013090965","volume":"25","author":"R Haynes","year":"2014","unstructured":"Haynes, R.  et al. Effects of lowering LDL cholesterol on progression of kidney disease. J. Am. Soc. Nephrol. 25, 1825\u20131833 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrcardio201648_CR81","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2174\/15701611113119990147","volume":"13","author":"PI Georgianos","year":"2015","unstructured":"Georgianos, P. I., Sarafidis, P. A. & Lasaridis, A. N. Arterial stiffness: a novel cardiovascular risk factor in kidney disease patients. Curr. Vasc. Pharmacol. 13, 229\u2013238 (2015).","journal-title":"Curr. Vasc. Pharmacol."},{"key":"BFnrcardio201648_CR82","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","volume":"3","author":"D de Zeeuw","year":"2015","unstructured":"de Zeeuw, D.  et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 3, 181\u2013190 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"BFnrcardio201648_CR83","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1517\/14740338.2015.1085504","volume":"14","author":"B Philips","year":"2015","unstructured":"Philips, B. & MacPhee, I. Do statins prevent acute kidney injury? Expert Opin. Drug Saf. 14, 1547\u20131561 (2015).","journal-title":"Expert Opin. Drug Saf."},{"key":"BFnrcardio201648_CR84","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/fca.14.82","volume":"11","author":"EM Roth","year":"2015","unstructured":"Roth, E. M. & McKenney, J. M. ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol. 11, 27\u201337 (2015).","journal-title":"Future Cardiol."},{"key":"BFnrcardio201648_CR85","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M13-2453","volume":"160","author":"M Tonelli","year":"2014","unstructured":"Tonelli, M. & Wanner, C. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann. Intern. Med. 160, 182 (2014).","journal-title":"Ann. Intern. Med."},{"key":"BFnrcardio201648_CR86","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone, N. J.  et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 129, S1\u2013S45 (2014).","journal-title":"Circulation"},{"key":"BFnrcardio201648_CR87","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1681\/ASN.2014090952","volume":"26","author":"M Tonelli","year":"2015","unstructured":"Tonelli, M. We don't prescribe statins to lower cholesterol: we prescribe statins to reduce vascular risk. J. Am. Soc. Nephrol. 26, 1001\u20131003 (2015).","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2016.48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2016.48","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2016.48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:58:54Z","timestamp":1684468734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2016.48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,7]]},"references-count":87,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["BFnrcardio201648"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2016.48","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,7]]},"assertion":[{"value":"7 April 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}